SAVA: DEF 14A · proxy statement
Filana Therapeutics, Inc. (formerly Cassava Sciences) has filed its definitive proxy statement for the 2026 annual meeting scheduled for June 11, 2026. The board is asking stockholders to approve an amendment to the 2018 Omnibus Incentive Plan to increase the authorized share reserve by 4,000,000 shares to a total of 9,000,000 shares, citing the need to remain competitive in attracting talent. The proposal also seeks to extend the plan's expiration date to January 31, 2030, and implement new governance limits on awards to non-employee directors and officers. The proxy includes the election of three Class II directors: Richard J. Barry, Pierre Gravier, and Claude Nicaise, M.D. Notably, two long-serving directors, Dr. Robert Gussin and Michael O'Donnell, are stepping down from the board at the conclusion of the meeting. Additionally, the filing requests the ratification of Ernst & Young LLP as the independent auditor and includes a non-binding advisory vote on 2025 executive compensation.
